Tenzing Acquisition Corp.

The company is no longer listed on Nasdaq. Cash rose 38% over the half-year entirely through equity issuance while R&D spending fell about 63% year over year.

Every date given is conditional: the 2046 exclusivity depends on a patent application that has been filed and not granted, and RECOVER-2 enrollment is expressly conditioned on financing the company has not yet raised.

A dated meeting and a record date are what a holder needs in order to act, and this version supplies both — but the record date of November 4, 2020 had already passed when the amendment was filed on November 6, 2020, so anyone buying after it cannot vote. The registered amounts are unchanged from the previous amendment: 10,941,934 shares of common stock and 6,683,813 warrants, of which only 5,807,381 shares are the maximum estimated to be issued in the business combination itself. Tenzing continues into Delaware as Reviva Pharmaceuticals Holdings, Inc.

The fee table decomposes the 10,941,934 shares, and the decomposition is the whole ownership picture: only 5,807,381 are the maximum the registrant estimates will be issued in the business combination itself, against 3,194,490 shares from the initial public offering, 1,581,250 the sponsor bought in a private placement before the IPO, and 358,813 issued in private placements at the IPO. The 6,683,813 warrants are 6,325,000 from the IPO and 358,813 private, and they carry through the Domestication into warrants for the same number of shares on the same terms.

The registration statement breaks the share count into its parts, which is unusually legible: 5,807,381 shares are the maximum estimated to be issued in the business combination itself, 3,194,490 are IPO shares already outstanding, 1,581,250 were bought by the sponsor in a private placement before the IPO, and 358,813 were sold in private placements alongside it. The existing shares appear only because the BVI-to-Delaware continuation converts them by operation of law. The warrants are likewise split: 6,325,000 from the IPO and 358,813 private.

Most of the registered stock is not new: of the 10,941,934 shares, only 5,807,381 are the maximum estimated to be issued in the business combination itself, while 3,194,490 are IPO shares, 1,581,250 are the sponsor's pre-IPO private placement shares and 358,813 came from private placements at the IPO — all converting by operation of law in the Domestication. Fee pricing used $10.725, the August 11, 2020 Nasdaq high-low average. The warrants are 6,325,000 from the IPO plus 358,813 issued privately.

What changed: Q2 2026 10-Q of Reviva Pharmaceuticals Holdings, Inc. (RVPH). The cover states the common stock is quoted on the OTCQB Venture Market, quotation having commenced May 14, 2026 upon suspension from The Nasdaq Capital Market, with Nasdaq filing a Form 25 on July 10, 2026 to strike the stock from listing. Why it matters: The company is no longer listed on Nasdaq. Cash rose 38% over the half-year entirely through equity issuance while R&D spending fell about 63% year over year.

What changed: Exhibit 99.1 to an 8-K of Reviva Pharmaceuticals Holdings, Inc. (OTCQB: RVPH): the August 12, 2026 press release reporting Q2 2026 results. Net loss was approximately $2.4 million, or $(0.19) per share, versus approximately $6.1 million, or $(2.40) per share, with all share and per-share amounts retrospectively adjusted for the one-for-twenty reverse stock split effected March 9, 2026. Cash and equivalents were approximately $19.9 million at June 30, 2026 versus $14.4 million at December 31, 2025. Why it matters: Every date given is conditional: the 2046 exclusivity depends on a patent application that has been filed and not granted, and RECOVER-2 enrollment is expressly conditioned on financing the company has not yet raised.